Memory Pharmaceuticals Corp. (MEMY) announced the issuance of U.S. Patent, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia.
The company said that the term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.
The company also said it is currently conducting a Phase 2 trial for R3487/MEM 3454 in CIAS. Memory Pharma recently announced the completion of its Phase 1 program for R4996/MEM 63908 and it expects to report the top-line data from that program in the fourth quarter of 2008.
For comments and feedback: editorial@rttnews.com